Featured Story

CalTech team creates one-time contraceptive vaccine for feral animals

Scientists have already made strides with immunotherapies, or treatments that spur the immune system to fight diseases. But now researchers at the California Institute of Technology are taking the technology one step further, developing a one-time contraceptive vaccine that uses hormone antibodies to spay or neuter animals.

Merial CEO Hellmann on eliminating rabies and reinventing disease prevention

When rumors emerged in late September that Sanofi might be considering spinning off its high-flying animal health division, Merial, the unit's CEO, Carsten Hellmann, didn't let the media attention distract him from his mission. "In the last couple of quarters, Merial has been doing very well. We're growing fast, and that's what I'm focusing on right now," Hellmann said.

New book spotlights growing role of dogs in cancer research

Ever since I took over as contributing editor and primary writer of FierceAnimalHealth in 2014, I have featured several stories about a burgeoning field of research known as "comparative oncology," in which veterinarians and oncologists work together to investigate potential new cures for tumor types that are similar in people and dogs (and sometimes even cats).

International health groups vow renewed effort to eradicate rabies

Sept. 28 was World Rabies Day, an annual campaign sponsored by the Centers for Disease Control and the Alliance for Rabies Control, but this year's event was an international affair. Four global health organizations marked the occasion by publishing a call to action for all countries to invest in rabies-control programs, focusing particularly on vaccinating dogs.

FDA seeks veterinarians' input on antibiotics resistance

As part of a multifaceted effort to combat antibiotics resistance, the FDA is distributing a survey to veterinarians who specialize in treating horses, cows and other ruminants, which are animals that obtain most of their nutrients by grazing.


From Our Sister Sites


When the FDA last year yanked away its initial approval of Ranbaxy's generics of two blockbusters including the heartburn med Nexium, the Indian drugmaker fired back with a lawsuit against the FDA. But Ranbaxy is now owned by Sun Pharmaceutical, which sees no upside to fighting with the agency, and so it has dropped the litigation.


Credit Suisse analyst Vamil Divan is optimistic about sales of Eli Lilly and Boehringer Ingelheim's Jardiance. He's raised his rating on Lilly to outperform, lifting his stock price target to $105--25% above Thursday's closing price of $83.77.